Prostate cancer is a hormone-dependent tumor that can be resected radically in the early stages of the disease and when the patient’s condition permits, and most patients require drug therapy, which also includes preoperative and postoperative treatment for some patients undergoing radical surgery. Therefore, drug therapy plays a very important role in prostate cancer. There are two types of pharmacological treatments for prostate cancer, one is to directly affect the conversion of dihydrotestosterone into testosterone, the effect of which is to directly block the binding of dihydrotestosterone (DHT) to androgen receptor (AR), blocking the effect of androgens on prostate cancer cells, causing the tumor cells to “starve” and causing apoptosis. The most representative drug is Flutamide, the same product is also imported Flutamide (trade name slow receding tumor or Fuzil), the pharmacological effect of the two is exactly the same. The other class of drugs is LH-RH mimetic, so that the secretion of testosterone (androgen) by the testes and adrenal glands is inhibited, thus reducing and eliminating androgenic effects. Therefore, it can replace orchiectomy in clinical practice, called drug depot. The representative drugs are Inhibiton, Norelide, etc. No matter it is surgical depot (orchiectomy) or drug depot (LH-RH mimetic), androgen antagonist should be applied at the same time, because adrenaline can also secrete androgens, accounting for about 30% of the total androgens, so depot treatment is not complete, and androgen supplementation therapy is needed, also called full androgen blockade. Whether it is surgical debridement (orchiectomy) or pharmacological debridement (application of LH-RH mimetic) and combined application of anti-androgen therapy (flutamide or retardation tumor, etc.), serum prostate-specific antigen (PSA) and FPSA can be significantly reduced, about 3 months to below normal low levels, and can be maintained for a long time. However, there are some individual patients with this treatment, PSA decline is not obvious, or the decline is very small, or may reach a certain level and then no longer decline, the symptoms do not improve. The reason for this is determined by the biological characteristics of the tumor, which may be an androgen non-dependent tumor, so the application of anti-androgen drugs such as flutamide is ineffective, rather than the cause of the drug itself, which requires a change in drug therapy. There is another situation that the effect is good in the early stage of applying conventional treatment such as flutamide, but after a longer period of time (usually more than 9 months), there is a gradual increase of PSA and FPSA, that is, it is useless to increase the drug dose. This indicates that the tumor is transformed from the original androgen-dependent to non-dependent, and the tumor characteristics become androgen-resistant, and the failure of continued treatment occurs. This change in therapeutic effect is caused by the change in the nature of the tumor rather than the failure of the original drug. Treatment of such tumors requires another class of drugs, such as estradiol phosphate nitrogen mustard or chemotherapeutic agents, or a change in treatment regimen. Therefore, up to now, there is no definite conclusion at home or abroad about how long to use prostate cancer medication, how to avoid the tumor changing from androgen-dependent to non-dependent, and whether the medication should be used in gradually decreasing doses or intermittently. At present, it is preferred to stop the drug after applying it to a normal low level for a period of time (6-9 months), which can reduce the side effects of the drug and also reduce or maintain the generation of hormone non-dependent tumors, as well as save money and improve the quality of life (improve symptoms such as weakness, false sweating and easy fatigue). Resume medication when PSA returns to 4 mcg/mL after discontinuation. Of course when to stop and when to resume medication is still being worked out and is determined specifically by each individual case. There are many treatments for advanced prostate cancer, especially androgen non-dependent, including androgen, chemotherapy and radiotherapy treatment, but the overall treatment effect is not the most ideal, and it is important to try to avoid androgen non-dependent tumors.